Skip to main content
SpringerLink
Log in

Views on the Therapeutic Needs of Older Adults

  • Chapter
  • First Online:
Developing Drug Products in an Aging Society

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 26))

  • 1323 Accesses

Abstract

A few decades ago a term was coined for pediatric drug development, or lack thereof, calling children “therapeutic orphans.” Since then, tremendous strides have been made in developing drugs to benefit children. We are in a similar conundrum now for drugs of the older adults. Therefore, it is appropriate to mention that the current situation for the older adults is that of “therapeutic overlook.” Perhaps this recognition can set the wheels in motion to seriously understand the issues related to the older adults from a clinical perspective and also from the viewpoint of sociocultural and physical limitations that come with advancing age.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Al-Khattawi A, Mohammed AR. Challenges and emerging solutions in the development of compressed orally disintegrating tablets. Expert Opin Drug Discov. 2014;9:1109–20.

    Article  CAS  PubMed  Google Scholar 

  2. Al-Tawil N, Odar-Cederlöf I, Berggren AC, Johnson HE, Persson J. Pharmacokinetics of transdermal buprenorphine patch in the elderly. Eur J Clin Pharmacol. 2013;69:143–9.

    Article  CAS  PubMed  Google Scholar 

  3. Allen S. Are inhaled systemic therapies a viable option for the treatment of the elderly patient? Drugs Aging. 2008;25:89–94.

    Article  PubMed  Google Scholar 

  4. Australian Institute of Health and Welfare. Older Australia at a glance. 4th ed. Cat. no. AGE 52. Canberra: AIHW; 2007.

    Google Scholar 

  5. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther. 1998;20:764–71.

    Article  CAS  PubMed  Google Scholar 

  6. Barrett JS, Della Casa Alberighi O, Läer S, Meibohm B. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther. 2012;92:40–9.

    Google Scholar 

  7. Blosser CD, Huverserian A, Bloom RD, Abt PD, Goral S, Thomasson A, Shults J, Reese PP. Age, exclusion criteria, and generalizability of randomized trials enrolling kidney transplant recipients. Transplantation. 2011;91:858–63.

    Google Scholar 

  8. Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv. 2007;4:37–45.

    Article  CAS  PubMed  Google Scholar 

  9. Broadway DC, Cate H. Pharmacotherapy and adherence issues in treating elderly patients with glaucoma. Drugs Aging. 2015;32:569–81.

    Article  CAS  PubMed  Google Scholar 

  10. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3:383–9.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Chien JY, Ho RJY. Drug delivery trends in clinical trials and translational medicine: evaluation of pharmacokinetic properties in special populations. J Pharm Sci. 2011;100:53–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet. 2009;374:1196–208.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Cohen-Mansfield J. Recruitment rates in gerontological research: the situation for drug trials in dementia may be worse than previously reported. Alzheimer Dis Assoc Disord. 2002;16:279–82.

    Article  CAS  PubMed  Google Scholar 

  14. Coupland JN, Hayes JE. Physical approaches to masking bitter taste: lessons from food and pharmaceuticals. Pharm Res. 2014;31:2921–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Della Casa Alberighi O, Barrett JS, Läer S, Meibohm B. Response to “physiologically based pharmacokinetic modeling at the extremes of age.” Clin Pharmacol Ther. 2013;93:149.

    Google Scholar 

  16. Divoll M, Greenblatt DJ, Ochs HR, Shader RI. Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. Anesth Analg. 1983;62:1–8.

    Article  CAS  PubMed  Google Scholar 

  17. Food and Drug Administration. Guidance for industry: guideline for the study of drugs likely to be used in the elderly. 1989. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072048.pdf.

  18. Food and Drug Administration. Guidance for industry: content and format for geriatric labeling. 2001. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075062.pdf.

  19. Food and Drug Administration. Guidance for industry: general considerations for the clinical evaluation of drugs. 1997. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071682.

  20. Food and Drug Administration. Guidance for industry: providing clinical evidence of effectiveness for human drug and biological products. 1998. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072008.pdf.

  21. Food and Drug Administration. Guidance for industry: exposure-response relationships—study design, data analysis, and regulatory applications. 2005. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072109.pdf.

  22. Food and Drug Administration. Guidance for industry: population pharmacokinetics. 1999. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072137.pdf.

  23. Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2003. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072123.pdf.

  24. Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labeling. Draft guidance. 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf.

  25. Food and Drug Administration. Guidance for industry: drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. Draft guidance. 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.

  26. Francoeur M, Ahmed I, Sitek S, et al. Age-related differences in ophthalmic drug disposition III. Corneal permeability of pilocarpine in rabbits. Int J Pharm. 1983;16:203–13.

    Article  CAS  Google Scholar 

  27. Fries JF. Aging, natural death, and the compression of morbidity. N Engl J Med. 1980;303:130–5.

    Article  CAS  PubMed  Google Scholar 

  28. Fries JF, Bruce B, Chakravarty E. Compression of morbidity 1980–2011: a focused review of paradigms and progress. J Aging Res. 2011;2011:1–10.

    Article  Google Scholar 

  29. Harvey PT. Common eye diseases of elderly people: identifying and treating causes of vision loss. Gerontology. 2003;49:1–11.

    Article  PubMed  Google Scholar 

  30. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162:1682–8.

    Article  PubMed  Google Scholar 

  31. Henry RR, Mudaliar S, Chu N, Kim D, Armstrong D, Davis TT, An B, Reinhardt RR. Young and elderly type 2 diabetic patients inhaling insulin with the AERx® insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison. J Clin Pharmacol. 2003;43:1228–34.

    Article  CAS  PubMed  Google Scholar 

  32. Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85:86–8.

    Article  CAS  PubMed  Google Scholar 

  33. Holazo YR, Winkler MB, Patel IH. Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics. J Clin Pharmacol. 1988;28:1040–5.

    Article  CAS  PubMed  Google Scholar 

  34. Johnston C, Kirkpatrick CM, McLachlan AJ, Hilmer SN. Physiologically based pharmacokinetic modeling at the extremes of age. Clin Pharmacol Ther. 2013;93:148.

    Article  CAS  PubMed  Google Scholar 

  35. Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M, Hall SD. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97:247.

    Article  CAS  PubMed  Google Scholar 

  36. Kaestli LZ, Wasilewski-Rasca AF, Bonnabry P, Vogt-Ferrier N. Use of transdermal drug formulations in the elderly. Drugs Aging. 2008;25:269–80.

    Article  CAS  PubMed  Google Scholar 

  37. Ke TL, Clark AF, Gracy RW. Age-related permeability changes in rabbit corneas. J Ocul Pharmacol Ther. 1999;15:513–23.

    Article  CAS  PubMed  Google Scholar 

  38. Ke AB, Rostami-Hodjegan A, Zhao P, Unadkat JD. Pharmacometrics in pregnancy: an unmet need. Annu Rev Pharmacol Toxicol. 2014;54:53–69.

    Article  CAS  PubMed  Google Scholar 

  39. Kirkwood TB. Systems biology of ageing and longevity. Philos Trans R Soc B. 2011;366:64–70.

    Article  Google Scholar 

  40. Klotz U. The elderly—a challenge for appropriate drug treatment. Eur J Clin Pharmacol. 2008;64:225–6.

    Article  PubMed  Google Scholar 

  41. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67–76.

    Google Scholar 

  42. Kuno N, Fujii S. Recent advances in ocular drug delivery systems. Polymers. 2011;3:193–221.

    Article  CAS  Google Scholar 

  43. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons in published randomized trials of acute coronary syndromes. JAMA. 2001;286:708–13.

    Article  CAS  PubMed  Google Scholar 

  44. Leppik IE. Epilepsy in the elderly. Epilepsia. 2006;47(Suppl 1):65–70.

    Article  PubMed  Google Scholar 

  45. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ. Participation of patients 65 years of age and older in cancer clinical trials. J Clin Oncol. 2003;21:1383–9.

    Article  PubMed  Google Scholar 

  46. MacLaughlin EJ, Raehl CL, Treadway AK, Sterling TL, Zoller DP, Bond CA. Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging 2005;22:231–55.

    Google Scholar 

  47. Mangoni AA, Jansen PAF, Jackson SHD.: Under-representation of older adults in pharmacokinetic and pharmacodynamic studies: a solvable problem? Expert Rev Clin Pharmacol. 2013;6:35–9.

    Google Scholar 

  48. Matsuura T, Oda Y, Tanaka K, Mori T, Nishikawa K, Asada A. Advance of age decreases the minimum alveolar concentrations of isoflurane and sevoflurane for maintaining bispectral index below 50. Br J Anaesth. 2009;102:331–5.

    Article  CAS  PubMed  Google Scholar 

  49. Messina R, Becker R, van Riet-Nales DA, Stegemann S. Results from a preliminary review of scientific evidence for appropriateness of preparations, dosage forms and other product design elements for older adult patients. Int J Pharm. 2015;478:822–8.

    Article  CAS  PubMed  Google Scholar 

  50. Morse AN, Labin LC, Young SB, Aronson MP, Gurwitz JH. Exclusion of elderly women from published randomized trials of stress incontinence surgery. Obstet Gynecol. 2004;104:498–503.

    Article  PubMed  Google Scholar 

  51. Myint PK, Welch AA. Healthier ageing. BMJ. 2012;344:42–5.

    Article  Google Scholar 

  52. Park DC, Hertzog C, Leventhal H, Morrell RW, Leventhal E, Birchmore D, Martin M, Bennett J. Medication adherence in rheumatoid arthritis patients: older is wiser. J Am Geriatr Soc. 1999;47:172–83.

    Article  CAS  PubMed  Google Scholar 

  53. Perrie Y, Badhan RK, Kirby DJ, Lowry D, Mohammed AR, Ouyang D. The impact of ageing on the barriers to drug delivery. J Control Release. 2012;161:389–98.

    Article  CAS  PubMed  Google Scholar 

  54. Polasek TM, Patel F, Jensen BP, Sorich MJ, Wiese MD, Doogue MP. Predicted metabolic drug clearance with increasing adult age. Br J Clin Pharmacol. 2013;75:1019–28.

    Article  CAS  PubMed  Google Scholar 

  55. Quinn HL, Hughes CM, Donnelly RF. Novel methods of drug administration for the treatment and care of older patients. Int J Pharm. 2016 Jan 22 (Epub ahead of print, PMID: 26807530).

    Google Scholar 

  56. Reeve E, Wiese MD, Mangoni AA. Alterations in drug disposition in older adults. Expert Opin Drug Metab Toxicol. 2015;11:491–508.

    Article  PubMed  Google Scholar 

  57. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011;51:45–73.

    Article  CAS  PubMed  Google Scholar 

  58. Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: concepts and applications. 4th ed. Lippincott Williams & Wilkins Publisher; 2011.

    Google Scholar 

  59. Rowland Yeo K, Aarabi M, Jamei M, Rostami-Hodjegan A. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol. 2011;4:261–74.

    Google Scholar 

  60. Ryan T. The ageing of the blood supply and the lymphatic drainage of the skin. Micron. 2004;35:161–71.

    Article  CAS  PubMed  Google Scholar 

  61. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22–33.

    PubMed  Google Scholar 

  62. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther. 2007;82:87–96.

    Google Scholar 

  63. Schwartz JB, Abernethy DR. Aging and medications: past, present, future. Clin Pharmacol Ther. 2009;85:3–10.

    Article  Google Scholar 

  64. Schwartz JB, Verotta D. Population analyses of atorvastatin clearance in patients living in the community and in nursing homes. Clin Pharmacol Ther. 2009;86:497–502.

    Google Scholar 

  65. Ship JA, Pillemer SR, Baum BJ. Xerostomia and the geriatric patient. J Am Geriatr Soc. 2002;50:535–43.

    Article  PubMed  Google Scholar 

  66. Shirkey H. Editorial comment: therapeutic orphans. J Pediatr. 1968;72:119–20.

    Article  CAS  PubMed  Google Scholar 

  67. Siekmeier R, Scheuch G.: Inhaled insulin—does it become reality? J Physiol Pharmacol. 2008;6(59):81–113.

    Google Scholar 

  68. Stegemann S. Challenges and opportunities in the design of age-appropriate drug products. Z Gerontol Geriatr. 2012;45:479–84.

    Google Scholar 

  69. Stegemann S, Gosch M, Breitkreutz J. Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm. 2012;430:197–206.

    Google Scholar 

  70. Thompson CM, Johns DO, Sonawane B, Barton HA, Hattis D, Tardif R, Krishnan K. Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly. J Toxicol Environ Health B Crit Rev. 2009;12:1–24.

    Article  PubMed  Google Scholar 

  71. Tsamandouras N, Rostami-Hodjegan A, Aarons L: Combining the “bottom-up” and “top-down” approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol. 2015;79:48–55.

    Google Scholar 

  72. United Nations Department of Economic and Social Affairs Population Division. Profiles of ageing 2013. 2013. http://www.un.org/en/development/desa/population/publications/dataset/urban/profilesOfAgeing2013.shtml.

  73. United Nations, Department of Economic and Social Affairs, Population Division. World population ageing 2013. 2013. ST/ESA/SER.A/348.

    Google Scholar 

  74. Vadivelu N, Hines RL. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin Interv Aging. 2008;3:421–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Vincent GK, Velkoff VA. The next four decades the older population in the United States: 2010 to 2050. Current population reports, P25-1138. Washington, DC: U.S. Census Bureau. http://www.census.gov/prod/2010pubs/p25-1138.pdf.

Download references

Disclaimer

This chapter reflects the views and opinions of the authors and does not represent the views and opinions of the authors’ present and former employers.

Author information

Authors and Affiliations

  1. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Translational Sciences, Office of Clinical Pharmacology, Silver Spring, MD, 20993, USA

    S. W. Johnny Lau & Raman K. Baweja

Authors
  1. S. W. Johnny Lau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raman K. Baweja
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. W. Johnny Lau .

Editor information

Editors and Affiliations

  1. Graz University of Technology, Graz, Austria

    Sven Stegemann

Rights and permissions

Reprints and permissions

Copyright information

© 2016 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Lau, S.W.J., Baweja, R.K. (2016). Views on the Therapeutic Needs of Older Adults. In: Stegemann, S. (eds) Developing Drug Products in an Aging Society. AAPS Advances in the Pharmaceutical Sciences Series, vol 26. Springer, Cham. https://doi.org/10.1007/978-3-319-43099-7_35

Download citation

Publish with us

Policies and ethics

Search

Navigation